Skip to content

HN-BIO: A Study of Head and Neck MRI and Tumor Microenvironment Biomarkers

Squamous Cell Carcinoma of Head and Neck

The purpose of this study is to explore biomarker development in patients with newly diagnosed Head and neck squamous cell carcinoma (HNSCC) receiving curative therapy.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Age \>/= 18 years
* Histologically proven Head and Neck Squamous Cell carcinoma
* Primary or nodal disease \> 3cm for biomarker imaging
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
* Planned for curative surgery or (chemo)radiotherapy
* Willingness to undergo repeat MRI imaging
* Able to receive and understand verbal and written information regarding study and able to give written informed consent
* Adequate renal function: Calculated creatinine clearance \>/= 30ml/min
* Be able to lie comfortably on back for 1 hour

Exclusion Criteria:

* As judged by investigator evidence of systemic disease that makes unsuitable for study
* Contra-indication for serial MRI scans
* Previous solid tumor treated within last 5 years
* Pregnancy
* History of gadolinium contrast allergy
* Non-reversible clotting abnormality

Study Location

Princess Margaret Cancer Center
Princess Margaret Cancer Center
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Andrew McPartlin, MD

[email protected]
416-946-2132
Study Sponsored By
University Health Network, Toronto
Participants Required
More Information
Study ID: NCT06085781